Hurst D L
Department of Neurology, Texas Tech University Health Sciences Center, Lubbock, USA.
Seizure. 1996 Mar;5(1):47-50. doi: 10.1016/s1059-1311(96)80062-8.
Currently valproic acid is considered to be the drug of first choice for juvenile myoclonic epilepsy (JME) resulting in a 70-90% control rate for all seizure types associated with JME. In those situations where valproic acid fails to control seizure activity, results in unacceptable side-effects, or is declined due to potential side-effects, an alternative effective monotherapy would be desirable. Five adolescent female patients were placed on methsuximide for JME. All five patients have been seizure free with the use of methsuximide and four out of five are now on methsuximide monotherapy with good success. C.L. has now had complete seizure control on methsuximide monotherapy, a total of 1200 mg a day, for 7 years with the exception of one seizure event occurring on an attempted discontinuation of methsuximide after being 5 years seizure free. Methsuximide monotherapy as demonstrated in these five patients is an effective treatment for JME.
目前，丙戊酸被认为是青少年肌阵挛性癫痫（JME）的首选药物，对与JME相关的所有癫痫发作类型的控制率达70%-90%。在丙戊酸未能控制癫痫活动、导致不可接受的副作用或因潜在副作用而被拒绝使用的情况下，需要一种替代的有效单一疗法。五名青春期女性患者因JME接受甲琥胺治疗。所有五名患者使用甲琥胺后均无癫痫发作，五名中有四名目前接受甲琥胺单一疗法，效果良好。C.L.目前在每天1200毫克甲琥胺单一疗法下已完全控制癫痫发作7年，在无癫痫发作5年后试图停用甲琥胺时发生过一次癫痫发作。这五名患者所证明的甲琥胺单一疗法是治疗JME的一种有效疗法。
